RemeGen Co

RemeGen Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of RemeGen Co (688331.SS) as of Oct 26, 2026 is -20.30 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 98.15 % — a change of -120.68% (lower).

FCF Conversion

-20.30 %

YoY

-120.68%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of RemeGen Co is 2025 -20.30 % . FCF Conversion Rate (FCF/EBITDA) of RemeGen Co was 2024 98.15 % . It decreases by -120.68% lower compared to the previous year.

The RemeGen Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
78.44 CNY
Jan 1, 2019
80.87 CNY
Jan 1, 2020
163.50 CNY
Jan 1, 2021
-128.04 CNY
Jan 1, 2022
202.36 CNY
Jan 1, 2023
155.81 CNY
Jan 1, 2024
98.15 CNY
Jan 1, 2025
-20.30 CNY
The RemeGen Co FCF Conversion history
YEARFCF ConversionYoY
-20.30 %-120.68%
98.15 %-37.01%
155.81 %-23.00%
202.36 %-258.05%
-128.04 %-178.31%
163.50 %+102.18%
80.87 %+3.09%
78.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

FCF Conversion Rate (FCF/EBITDA) of RemeGen Co is -20.30 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of RemeGen Co changed from 98.15 % to -20.30 %, representing a -120.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s RemeGen Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RemeGen Co

All Key Metrics — RemeGen Co